Company Overview

Vireo Growth Inc. is a vertically integrated cannabis company operating primarily in the medical cannabis industry within the United States. The company focuses on the cultivation, processing, and retail distribution of regulated cannabis products, serving state-licensed medical markets. It operates through a holding company structure, with U.S.-based subsidiaries managing licensed operations in individual states. Its core revenue drivers are the production and sale of medical cannabis flower, extracts, and derivative products through company-owned dispensaries and wholesale channels.

The company traces its origins to 2014, when it was founded as Vireo Health by physician entrepreneur Kyle Kingsley. Over time, the business evolved into Vireo Growth Inc., a publicly traded parent entity designed to consolidate U.S. cannabis assets while accessing international capital markets. The company has emphasized physician-led clinical standards, regulatory compliance, and disciplined capital allocation as differentiators in the fragmented U.S. cannabis landscape.

Business Operations

Vireo Growth Inc. generates revenue through vertically integrated operations that include cultivation, manufacturing, and retail sales, primarily under its Vireo Health brand. Its operating model centers on controlling the full value chain in limited-license medical cannabis states, which includes indoor cultivation facilities, product manufacturing labs, and branded dispensaries. The company’s business segments are generally aligned by state-based operating subsidiaries rather than by product line.

Operations are conducted through subsidiaries such as Vireo Health of Minnesota LLC and Vireo Health of New York LLC, which hold state-issued licenses. The company’s assets include cultivation infrastructure, processing technology for oils and concentrates, and retail storefronts. Vireo Growth Inc. does not report material international operations, and its partnerships are primarily regulatory or operational in nature rather than large-scale joint ventures. Data on certain historical divestitures and partnership arrangements is inconclusive based on available public sources.

Strategic Position & Investments

Strategically, Vireo Growth Inc. has focused on strengthening its presence in limited-license medical markets and positioning itself for regulatory expansion, including potential adult-use legalization in select states. Growth initiatives have historically included selective acquisitions of in-state operators, license consolidation, and reinvestment in cultivation efficiency rather than rapid geographic expansion.

The company has made targeted investments in vertically integrated subsidiaries rather than maintaining a broad external investment portfolio. Its strategic posture emphasizes cash flow discipline and balance sheet management amid broader volatility in the U.S. cannabis sector. While the company has previously evaluated emerging cannabis formats and therapeutic applications, detailed disclosures regarding investments in novel technologies or non-plant-touching sectors are inconclusive based on available public sources.

Geographic Footprint

Vireo Growth Inc.’s operations are concentrated in the United States, with a presence in Minnesota, New York, Maryland, and New Mexico. These states represent the company’s core operating regions and account for substantially all of its assets and revenue-generating activities. The company’s headquarters are located in the United States, though the publicly traded parent entity is incorporated in Canada.

The company does not report active commercial operations outside North America. Its geographic strategy prioritizes regulatory stability and limited-license frameworks, rather than broad international expansion. Any historical operations or assets outside its current state footprint cannot be conclusively verified from available public disclosures.

Leadership & Governance

Vireo Growth Inc. was founded by Kyle Kingsley, who has played a central role in shaping the company’s physician-led and compliance-focused culture. The leadership team combines healthcare, regulatory, and financial experience, reflecting the company’s emphasis on operating within tightly regulated markets. Strategic vision has consistently emphasized disciplined growth, medical credibility, and long-term optionality tied to U.S. regulatory change.

Key executives include:

• Kyle Kingsley – Executive Chairman
• John Mazarakis – Chief Executive Officer
• Mark Weinswig – Chief Financial Officer

Information regarding additional senior executives, board committee structure, and governance policies is partially disclosed in public filings; however, certain details are inconclusive based on available public sources.